Functional interactions between tumor and peripheral nerve in a model of cancer pain in the mouse

Pain Medicine

Volumn 2, Issue 1, 2001, Pages 15-23

  Cain, David M ^a   Wacnik, Paul W ^a   Eikmeier, Laura ^a   Beitz, Alvin ^a   Wilcox, George L ^a   Simone, Donald A ^a,b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; CODEINE; ENDOTHELIN 1; FENTANYL; IBUPROFEN; MORPHINE; OPIATE; PARACETAMOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DESTRUCTION; BONE METASTASIS; CANCER INFILTRATION; CANCER PAIN; COLD SENSITIVITY; CONTROLLED STUDY; DISEASE SEVERITY; EXPERIMENTAL MODEL; EXTRACELLULAR FLUID; HUMAN; HYPERALGESIA; MOUSE; NERVE CONDUCTION; NOCICEPTION; NOCICEPTIVE RECEPTOR; NOCICEPTIVE STIMULATION; NONHUMAN; OSTEOSARCOMA; PERIPHERAL NERVE; PROTEIN SECRETION; RECEPTOR SENSITIVITY; TUMOR LOCALIZATION; TUMOR VOLUME;

EID: 0035002797     PISSN: 15262375     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1526-4637.2001.002001015.x     Document Type: Article

References (40)

1. Simmonds MA. Pharmacotherapeutic management of cancer pain: current practice. Semin Oncol 1997; 24(5 suppl 16):S16-1-6.
2. Elliot TE. Physician knowledge and attitudes about cancer pain management: a survey from the Minnesota Cancer Pain Project. J Pain Symptom Manage 1996;10:494-504.
3. Brose WG, Cousins MJ. Subcutaneous lidocaine for treatment of neuropathic cancer pain. Pain 1991;45: 145-8.
4. Brant JM. Cancer-related neuropathic pain. Nurse Pract Forum 1998;9:154-62.
5. O'Connell JX, Nanthakumar SS, Nielsen GP, Rosenberg AE. Osteoid osteoma: the uniquely innervated bone tumor. Mod Pathol 1998;11:175-80.
6. Payne R. Cancer pain mechanisms and etiology. Cancer Pain 1989;1-10.
7. Ossipov MH, Lopez Y, Nichols ML, Bian D, Porreca F. Inhibition by spinal morphine of the tail-flick response is attenuated in rats with nerve ligation injury. Neurosci Lett 1995;199:83-6.
8. Ossipov MH, Lopez Y, Nichols ML, Bian D, Porreca F. The loss of antinociceptive efficacy of spinal morphine in rats with nerve ligation injury is prevented by reducing spinal afferent drive. Neurosci Lett 1995;199:87-90.
9. Mercadante S. Malignant bone pain: pathophysiology and treatment. Pain 1997;69:1-18.
10. Wall PD. Neurological mechanisms in cancer pain. Cancer Surv 1988;7:127-40.
11. Pasternak GW. Multiple morphine and enkephalin receptors and die relief of pain. JAMA 1988;259: 1362-7.
12. Kenner DJ, Pain forum. Part 2. Neuropathic pain. Aust Fain Physician 1994;23:1279-83.
13. Diener KM. Biophosphonates for controlling pain from metastatic bone disease. Am J Health Syst Pharm 1996;53:1917-27.
14. Wacnik PW, Wilcox GL, Clohisy DR, Ramnaraine ML, Eikmeier LJ, Beitz AJ. Cancer Pain Mechanisms and Animal Models of Cancer Pain. Proc 9th World Congress on Pain 2000;16:615-37.
15. Maehara Y, Kusumoto H, Anai H, Kusumoto T, Sugimachi K. Human tumor tissues have higher ATP contents than normal tissues. Clin Chim Acta 1987;169:341-3.
16. Siems WG, Grune T, Schmidt H, Tikhonov YV, Pimenov AM. Purine nucleotide levels in host tissues of Ehrlich ascites tumor-bearing mice in different growth phases of the tumor. Cancer Res 1993;53: 5143-7.
17. Burnstock, G. A unifying purinergic hypothesis for the initiation of pain. Lancet 1996;347:1604-5.
18. Harland SP, Kuc RE, Pickard JD, Davenport AP. Characterization of endothelin receptors in human brain cortex, gliomas, and meningiomas. J Cardiovas Pharmacol 1995;26(suppl 3):S408-11.
19. Speciale L, Sarasella M, Ruzzante S, et al. Endothelin and nitric oxide levels in cerebrospinal fluid of patients with multiple sclerosis. J Neurovirol 2000; 6(suppl 2):S62-6.
20. Davar G, Hans G, Fareed MU, Sinnott C, Strichartz G. Behavioral signs of acute pain produced by application of endothelin-1 to rat sciatic nerve. Neuroreport. 1998;9:2279-83.
21. De-Melo JD, Tonussi CR, D'Orleans-Juste P, Rae GA. Articular nociception induced by endothelin-1, carrageenan and LPS in naive and previously inflamed knee-joints in the rat: inhibition by endothelin receptor antagonists. Pain 1998;77:261-9.
22. Raffa RB, Schupsky JJ, Jacoby HI. Endothelin-induced nociception in mice: mediation by ETA and ETB receptors. J Pharmacol Exp Ther 1996;276: 647-51.
23. Piovezan AP, D'Orleans-Juste P, Tonussi CR, Rae GA. Endothelins potentiate formalin-induced nociception and paw edema in mice. Can J Physiol Pharmacol 1997;75:596-600.
24. Piovezan AP, D'Orleans-Juste P, Souza GE, Rae GA. Endothelin-1-induced ET(A) receptor-mediated nociception, hyperalgesia and oedema in the mouse hind-paw: modulation by simultaneous ET(B) receptor activation. Br J Pharmacol 2000;129:961-8.
25. Piovezan AP, D'Orleans-Juste P, Tonussi CR, Rae GA. Effects of endothelin-1 on capsaicin-induced nociception in mice. Eur J Pharmacol 1998;351:15-22.
26. Asham EH, Loizidou M, Taylor I. Endothelin-1 and tumor development. Eur J Surg Oncol 1998;24: 57-60.
27. Bell KM, Chaplin DJ. The effect of oxygen and carbon dioxide on tumor cell endothelin-1 production. J Cardiovasc Pharmacol 1998;31(suppl 1):S537-40.
28. Pirtskhalaishvili G, Nelson JB. Endothelium-derived factors as paracrine mediators of prostate cancer progression. Prostate 2000;44:77-87.
29. Watanabe K., Hiraki H, Tanigawa T, et al. Immunohistochemical localization of endothelin-1, endothelin-3 and endothelin receptors in human pheochromocytoma and paraganglioma. Pathol Int 1997; 47:540-6.
30. Clohisy DR, Ogilvie CM, Carpenter RJ, Ramnaraine ML. Localized, tumor-associated osteolysis involves the recruitment and activation of osteoclasts. J Orthop Res 1996;80:1588-94.
31. Schwei MJ, Honore P, Rogers SD, et al. Neurochemical and cellular reorganization of the spinal cord in a murine model of bone cancer pain. J Neurosci 1999;19:10886-97.
32. Goldie RG. Endothelins in health and disease: an overview. Clin Exp Pharmacol Physiol 1999;26:145-8.
33. Goldie RG, Fernandes LB. A possible mediator role for endothelin-1 in respiratory disease. Monaldi Arch Chest Dis 2000;55:162-7.
34. Meidan R, Milvae RA, Weiss S, Levy N, Friedman A. Intraovarian regulation of luteolysis. J Reprod Fertil Suppl 1999;54:217-28.
35. van den Buuse M, Webber KM. Endothelin and dopamine release. Prog Neurobiol 2000;60:385-405.
36. Egidy G, Juillerat-Jeanneret L. Korth P, Bosman FT, Pinet F. The endothelin sytem in normal human colon. Am J Physiol Gastrointest Liver Physiol 2000;279:G211-22.
37. Hay DW. Putative mediator role of endothelin-1 in asthma and other lung diseases. Clin Exp Pharmacol Physiol 1999;26:168-71.
38. Pomonis JD, Mantyh PW, Rogers SD, Ghilardi JR. Endothelin B receptors are expressed by supporting cells in peripheral nerve: evidence for the involvement of supporting cells in nociceptive signaling. American Pain Society Abstracts. 1999.
39. Kushahara M, Yamaguchi K, Nagasaki K, et al. Production of endothelin in human cancer cell lines. Cancer Res 1990;50:3257-61.
40. Nelson JB, Nguyen SH, Wu-Wong JR, et al. New bone formation in an osteoblastic tumor model is increased by endothelin-1 overexpression and decreased by endothelin A receptor blockade. Urology 1999; 53:1062-9.